Ignite Creation Date:
2024-05-05 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00490646
Status:
COMPLETED
Last Update Posted:
2016-03-10
First Post:
2007-06-21
Brief Title:
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced andor Metastatic Breast Cancer
Sponsor:
R-Pharm
Organization:
R-Pharm
Study Overview
Official Title:
Randomized Phase II Study of Ixabepilone Plus Trastuzumab vs Docetaxel Plus Trastuzumab in Female Subjects With Her2 Locally Advanced andor Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this randomized Phase 2 open-label study was to assess the response rate of participants with Human Epidermal Growth Factor Receptor 2 Her2 locally advanced andor metastatic breast cancer not previously treated with chemotherapy or trastuzumab to treatment with ixabepilone plus trastuzumab andor docetaxel plus trastuzumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Eudract No 2007-000721-21 | None | None | None |